nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.03.2018 | Original Article

Effect of Cholecalciferol therapy on serum FGF₂₃ in vitamin D deficient patients: a randomized clinical trial

verfasst von: T. Kamelian, F. Saki, M. Jeddi, M. H. Dabbaghmanesh, G. H. R. Omrani

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Fibroblast growth factor-23 plays an important role in regulating systemic phosphate homeostasis, and vitamin D metabolism. However, the effect of Cholecalciferol therapy on FGF₂₃ serum level in patients with vitamin D deficiency has not been studied, yet.

Materials and methods

This is a double-blind, randomized clinical trial on 119 vitamin D deficient patients in 2016. Biochemical variables of treatment and placebo groups were analyzed after 12 weeks of 50,000 IU of Cholecalciferol vs. placebo therapy once a week, by SPSS18.

Results

After Cholecalciferol therapy, delta of serum PTH in treatment group was less than the controls (P < 0.001). However, delta values of serum 25(OH)D₃, 1,25(OH)₂D₃ and FGF₂₃ in vitamin D treated group were more than the placebo-treated ones (P < 0.001, P = 0.002, and P = 0.04, respectively). Moreover, FGF₂₃ serum level in treatment group was associated with serum calcium (P = 0.005, r = −0.256), and serum 1,25(OH)₂D₃ (P < 0.001, r = 0.529).

Conclusions

We propose that in these patients 1,25(OH)₂D₃ has a positive association with serum FGF₂₃, and hypostasized that serum calcium might be a down regulator of serum FGF₂₃.

Yamashita T, Konishi M, Miyake A, Inui K, Itoh N (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265–28270CrossRefPubMed

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of FGF₂₃ demonstrates an essential physiological role of FGF₂₃ in phosphate and vitamin D metabolism. J Clin Invest 113:561–568CrossRefPubMedPubMedCentral

Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF₂₃ levels in ESRD. Clin J Am Soc Nephrol 5(1):110–116CrossRefPubMedPubMedCentral

Quarles LD (2012) Role of FGF₂₃ in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 318(9):1040–1048CrossRefPubMedPubMedCentral

Ranch D, Zhang MY, Portale AA, Perwad F (2011) Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res 26(8):1883–1890CrossRefPubMedPubMedCentral

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S (2004) Yamashita T.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429–435CrossRefPubMed

Prié D, Friedlander G (2010) Reciprocal control of 1,25-dihydroxyvitamin D and FGF₂₃ formation involving the FGF₂₃/Klotho system. Clin J Am Soc Nephrol 5(9):1717–1722CrossRefPubMed

Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, Haussler CA, Jurutka PW (2012) The role of vitamin D in the FGF₂₃, Klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 13(1):57–69CrossRefPubMedPubMedCentral

Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120–1125CrossRefPubMed

10.

Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337:116–122CrossRefPubMed

11.

Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF₂₃) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18:2600–2608CrossRefPubMed

12.

Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549CrossRefPubMed

13.

Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR (2005) Ghishan FK.1alpha, 25-dihydroxyvitamin D3 upregulates FGF₂₃ gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289(6):G1036–G1042CrossRefPubMed

14.

Ashouri E, Meimandi EM, Saki F, Dabbaghmanesh MH, Omrani GR, Bakhshayeshkaram M (2015) The impact of LRP5 polymorphism (rs556442) on calcium homeostasis, bone mineral density, and body composition in Iranian children. J Bone Miner Metab 33(6):651–657. doi:10.1007/s00774-014-0624-4 CrossRefPubMed

15.

Soliman AT, De Sanctis V, Elalaily R, Bedair S, Kassem I (2014) Vitamin D deficiency in adolescents.Indian. J Endocrinol Metab 18(Suppl 1):S9–S16

16.

Saki F, Dabbaghmanesh MH, Omrani GR, Bakhshayeshkaram M (2015) Vitamin D deficiency and its associated risk factors in children and adolescents in southern Iran. Public Health Nutr 8:1–6

17.

Saki F, Omrani GR, Pouralborz Y, Dabbaghmanesh MH (2017) Vitamin D deficiency and the associated factors in children with type 1 diabetes mellitus in southern Iran. Int J Diabetes Dev Ctries 37(1):78–84CrossRef

18.

Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest. 116:2062–2072CrossRefPubMedPubMedCentral

19.

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor-independent FGF₂₃ actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289(5):F1088–F1095CrossRefPubMed

20.

Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349CrossRefPubMed

21.

Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M (2005) Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 101:94–99CrossRef

22.

Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team (2014) Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate. Antivir Ther 19(6):613–618CrossRefPubMedPubMedCentral

23.

Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17(5):1305–1315CrossRefPubMed

24.

Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS (2012) Randomized trial assessing the effects of ergocalciferol administration on circulating FGF₂₃. Clin J Am Soc Nephrol 7(4):624–631CrossRefPubMedPubMedCentral

25.

Ghazi AA, Hosseinpanah F, Ardakani ME, Ghazi S, Hedayati M, Azizi F (2010) Effects of different doses of oral Cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in school children. Eur J Clin Nutr 64(12):1415–1422CrossRefPubMed

26.

Hruska KA, Rifas L, Cheng SL, Gupta A, Halstead L, Avioli L (1995) X-linked hypophosphatemic rickets and the murine Hyp homologue. Am J Physiol 268:357–362

27.

Liu S, Quarles LD (2004) FGF₂₃: the counter regulatory phosphaturic hormone for vitamin D-mediated hyperphosphatemia. J Bone Minner Res. 19:251

28.

Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288(6):E1101–E1109CrossRefPubMed

29.

Clinkenbeard EL, White KE (2016) Systemic control of bone homeostasis by FGF₂₃ signaling. Curr Mol Biol Rep 2(1):62–71CrossRefPubMedPubMedCentral

30.

David V, Dai B, Martin A, Huang J, Han X, Quarles LD (2013) Calcium regulates FGF-23 expression in bone. Endocrinology 154(12):4469–4482CrossRefPubMedPubMedCentral

Titel: Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial
verfasst von: T. Kamelian
F. Saki
M. Jeddi
M. H. Dabbaghmanesh
G. H. R. Omrani
Publikationsdatum: 01.03.2018
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 3/2018
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-017-0739-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency

Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control

The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies

Ultrasound variants of autoimmune thyroiditis in children and adolescents and their clinical implication in relation to papillary thyroid carcinoma development

Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients